Abbvie Inc. vs Moderna, Inc.
ABBV vs MRNA — side-by-side comparison from reported financials. ABBV leads 7, MRNA leads 4 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Moderna, Inc.
MRNA · Healthcare
$225.15+14.29%Strong
| Metric | ABBV | MRNA |
|---|---|---|
| Price | $276.43 | $225.15 |
| Market cap | $488B | $89.9B |
| Revenue (TTM) | $64.4B | $2.23B |
| Revenue growth | +1.8% | -53.4% |
| Net margin | 9.8% | -141.4% |
| Free cash flow | $18.2B | -$1.24B |
| Net cash (debt) | ($56.2B) | $5.21B |
| 1-year price return | +19.8% | +717.8% |
| P/E | 77.4 | 3.9 |
| P/E vs own history (cheap-side %) | 23% | 10% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -39% |
| Altman Z-score | 2.33 | 13.40 |
| CV checks passed | 9 of 11 | 6 of 11 |
| Employees | 57,000 | 4,700 |
Full résumé-style profiles: ABBV CV · MRNA CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.